News

In Europe, Coagadex (human coagulation factor X) is indicated for the treatment and preventive management of bleeding episodes and the control of bleeding during surgical procedures in patients

The meeting will be held on 29th March. Last November, the FDA classified the Nuplazid NDA as having priority review status with a target prescription drug user fee

The results from the initial trial are anticipated in the middle of this year, with the results from the second study expected soon thereafter. The FIT program features

The MoC with the Iran Food and Drug Administration, affiliated to the Ministry of Health and Medical Education, is aimed at initiating talks to explore the possibilities in

WHO Director-General Margaret Chan said the spread of the virus had gone from a mild threat to one of alarming proportions. Chan is due to convene an international

Epic Sciences president and CEO Murali Prahalad said: "We have entered into an era where biomarkers are beginning to direct therapeutic decisions. What remains difficult is clinical validation

The NDA will be considered officially filed 60 days from the date of the completion of the submission, or February 20, 2016. The FDA granted Priority Review to

Preclinical studies of RAD1901 have shown consistent and robust single agent anti-tumor activity in multiple wild type and ESR1-mutant breast cancer models and tumor regression when combined with

They have entered into an open-access global research partnership with the Structural Genomics Consortium (SGC) to discover and characterise novel drug targets for myeloma. In this first partnership